What is HC Wainwright’s Forecast for KTTA FY2025 Earnings?

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Stock analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Pasithea Therapeutics in a research report issued to clients and investors on Monday, December 8th. HC Wainwright analyst S. Nik anticipates that the company will earn ($1.50) per share for the year. HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.82) EPS and FY2028 earnings at ($0.87) EPS.

Pasithea Therapeutics (NASDAQ:KTTA) last released its earnings results on Thursday, November 13th. The company reported ($0.41) earnings per share for the quarter.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Monday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.00.

Pasithea Therapeutics Stock Performance

Pasithea Therapeutics stock opened at $1.16 on Wednesday. Pasithea Therapeutics has a 52 week low of $0.28 and a 52 week high of $3.85. The firm has a market capitalization of $8.63 million, a PE ratio of -0.23 and a beta of 0.21. The business’s 50-day simple moving average is $0.81 and its 200-day simple moving average is $0.78.

Institutional Investors Weigh In On Pasithea Therapeutics

Hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP acquired a new position in Pasithea Therapeutics during the 3rd quarter valued at about $26,000. Citadel Advisors LLC raised its stake in shares of Pasithea Therapeutics by 43.7% during the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after buying an additional 20,483 shares during the last quarter. Finally, AdvisorShares Investments LLC raised its stake in shares of Pasithea Therapeutics by 261.5% during the second quarter. AdvisorShares Investments LLC now owns 193,547 shares of the company’s stock worth $140,000 after buying an additional 140,000 shares during the last quarter. Institutional investors and hedge funds own 23.92% of the company’s stock.

Insider Activity at Pasithea Therapeutics

In other news, Director Lawrence Steinman bought 133,333 shares of Pasithea Therapeutics stock in a transaction that occurred on Friday, November 28th. The stock was purchased at an average cost of $0.75 per share, with a total value of $99,999.75. Following the completion of the transaction, the director directly owned 199,691 shares in the company, valued at $149,768.25. This trade represents a 200.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 199,999 shares of company stock valued at $149,999 in the last three months. Corporate insiders own 2.70% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.